Introduction: Although severe acute respiratory syndrome coronavirus-2 infection is causing mortality in considerable proportion of coronavirus disease-2019 (COVID-19) patients, however, evidence for the association of sex, age, and comorbidities on the risk of mortality is not well-aggregated yet. It was aimed to assess the association of sex, age, and comorbidities with mortality in COVID-2019 patients. Methods: Literatures were searched using different keywords in various databases. Relative risks (RRs) were calculated by RevMan software where statistical significance was set as p #x3c; 0.05. Results: COVID-19 male patients were associated with significantly increased risk of mortality compared to females (RR 1.86: 95% confidence interval [CI] 1.67–2.07; p #x3c; 0.00001). Patients with age ≥50 years were associated with 15.4-folds significantly increased risk of mortality compared to patients with age #x3c;50 years (RR 15.44: 95% CI 13.02–18.31; p #x3c; 0.00001). Comorbidities were also associated with significantly increased risk of mortality; kidney disease (RR 4.90: 95% CI 3.04–7.88; p #x3c; 0.00001), cereborovascular disease (RR 4.78; 95% CI 3.39–6.76; p #x3c; 0.00001), cardiovascular disease (RR 3.05: 95% CI 2.20–4.25; p #x3c; 0.00001), respiratory disease (RR 2.74: 95% CI 2.04–3.67; p #x3c; 0.00001), diabetes (RR 1.97: 95% CI 1.48–2.64; p #x3c; 0.00001), hypertension (RR 1.95: 95% CI 1.58–2.40; p #x3c; 0.00001), and cancer (RR 1.89; 95% CI 1.25–2.84; p = 0.002) but not liver disease (RR 1.64: 95% CI 0.82–3.28; p= 0.16). Conclusion: Implementation of adequate protection and interventions for COVID-19 patients in general and in particular male patients with age ≥50 years having comorbidities may significantly reduce risk of mortality associated with COVID-19.
Intervirology

中文翻译：

---

COVID-19 患者性别、年龄和合并症与死亡率的关联：系统回顾和荟萃分析


简介：尽管严重急性呼吸综合征冠状病毒 2 感染导致相当大比例的 2019 冠状病毒病 (COVID-19) 患者死亡，但是，性别、年龄和合并症与死亡风险之间关系的证据尚不充分。 -尚未汇总。其目的是评估 2019 新型冠状病毒 (COVID-2019) 患者的性别、年龄和合并症与死亡率之间的关系。方法：使用不同的关键词在不同的数据库中检索文献。相对风险（RR）由RevMan软件计算，其中统计显着性设置为p #x3c； 0.05。结果：与女性患者相比，COVID-19 男性患者的死亡风险显着增加（RR 1.86：95% 置信区间 [CI] 1.67–2.07； p #x3c；0.00001）。与年龄 #x3c;50 岁的患者相比，年龄≥50 岁的患者死亡风险显着增加 15.4 倍（RR 15.44：95% CI 13.02–18.31； p #x3c；0.00001）。合并症也与死亡风险显着增加有关；肾脏疾病（RR 4.90：95% CI 3.04–7.88； p #x3c；0.00001）、脑血管疾病（RR 4.78；95% CI 3.39–6.76； p #x3c；0.00001）、心血管疾病（RR 3.05：95% CI 2.20） –4.25； p #x3c；0.00001）、呼吸系统疾病（RR 2.74：95% CI 2.04–3.67； p #x3c；0.00001）、糖尿病（RR 1.97：95% CI 1.48–2.64； p #x3c；0.00001）、高血压（RR 1.95：95% CI 1.58–2.40； p #x3c；0.00001）和癌症（RR 1.89；95% CI 1.25–2.84； p = 0.002），但不是肝病（RR 1.64：95% CI 0.82–3.28； p = 0.16）。 结论：对一般 COVID-19 患者，特别是年龄≥50 岁且患有合并症的男性患者实施充分的保护和干预措施，可以显着降低与 COVID-19 相关的死亡风险。
 病毒间学